Back to library
Loading…
glp1 · JAMA · 2021
Discontinuing semaglutide in adults with overweight or obesity led to significant weight regain and a worsening of cardiometabolic risk factors compared to continued treatment.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Wilding JPH, Woods R, Kushner R; STEP 4 Investigators
Discontinuing semaglutide in adults with overweight or obesity led to significant weight regain and a worsening of cardiometabolic risk factors compared to continued treatment.